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EDUCATIONAL INTERVENTIONS TARGETING ADOLESCENTS 
 WITH ATOPIC DERMATITIS 
BECKY HWANG 
ABSTRACT 
Background 
As a chronic inflammatory skin disorder, atopic dermatitis (AD) often affects people of 
varying ages and has the potential to affect individuals for years to decades. AD is both a 
physical and emotional disease, often severely affecting adolescents. Adolescence is a 
critical period of development when patients suffering with AD must learn to manage 
their own disease. The associated pruritus and skin barrier defects can be severe and 
interfere with social and educational opportunities. As adolescents accept the 
responsibility of managing their own AD, the disease outcome will be directly affected 
by their actions.  
Literature Review Findings 
Currently, the first line treatment for majority of patients suffering from AD is 
centered around topical emollients, topical corticosteroids and avoidance of exacerbating 
factors. Even with these treatments however, relapses often occur due to improper 
management of treatment, treatment education, and comorbidities. As a result, relapses 
often increase patient’s psychological stress and dermatologic scarring while decreasing 
self-confidence; all of which culminate into a decrease in quality of life. 
An organized literature review was performed focusing on studies that addressed 
adjunctive treatment modalities to improve overall disease outcomes in AD patients ages 
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10-19. Research has indicated the effectiveness of educational interventions for 
adolescents that aim to teach patients how to better cope with the disease by introducing 
topical therapy training, support groups, and counseling interventions. These 
interventions equip the youth with knowledge, motivate them to self-manage their 
chronic condition, and reinforce healthy behaviors. Because of the success of these 
interventions, it is important for providers such as physician assistants (PAs) and 
physicians to learn how to recognize patients’ psychological stress and effectively 
implement education interventions. 
Proposed project 
  The purpose of this study is to create a continuing medical education (CME) 
presentation-based lecture summarizing the most recent literature regarding educational 
interventions, which will raise awareness in the medical community. A brief 90-minute 
course will be offered for CME credits to expand the knowledge base of providers and 
equip them with resources necessary to encourage age-appropriate behavioral 
modifications to prevent and minimize relapses. 
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INTRODUCTION 
Background 
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases 
and a major public health problem globally, with a prevalence of 10.7% in US children  
under 18 years old.1 In many cases, patients who are diagnosed with atopic dermatitis 
continue to have persistent disease throughout adulthood. In developed countries, 
especially Western societies, there seems to be an increase in incidence of atopic 
dermatitis.2 At the same time, there is increasing research to suggest that atopic dermatitis 
is associated with impaired psychosocial functioning, which can stem from perceived 
disease severity, pruritus, sleep disturbances, and social distress. The associated pruritus 
and skin barrier manifestations can be severe and interfere with social and educational 
opportunities. The current first-line treatment for the majority of patients suffering from 
AD is centered around topical corticosteroids and avoidance of exacerbating factors. 
However, there is evidence to suggest that education and psychological coping could 
improve long term quality of life (QoL) and disease severity.3,4 There is currently a lack 
of training programs for healthcare providers to carry out educational interventions that 
can improve long-term disease severity and QoL. It is essential for providers to employ 
educational and psychosocial interventions in order to equip the youth with knowledge, 
motivate them to self-manage their chronic condition, and reinforce healthy behaviors. 
This will empower young patients to make informed and responsible decisions about 
their health. 
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Statement of the Problem 
AD is often accompanied by severe chronic symptoms such as pruritus, sleep 
disturbance, and psychological stress, which can all have serious effectss on a patient’s 
quality of life.5 As the incidence of AD in youth has increased, there has been a 
correlative increase in psychological disease. Dermatological conditions have been 
shown to be associated with psychological comorbidity. Affected patients can present 
with behavioral problems mostly rooted in increased emotional dependency, anxiety and 
sleep disturbances.6 Pruritus, a major symptom, can contribute to mood changes and poor 
sleep quality.6 Additionally, when compared to peers of the same age group, those with 
AD are more susceptible to mental illnesses such as anxiety, depression, conduct disorder 
and ADHD.7,8 The chronically relapsing-remitting course of AD can develop into a long-
term economic and psychological burden in patients with persistent disease. Evidence 
from the literature suggests that good patient-provider rapport is central to effective 
treatment of AD. 
 While many studies examine on childhood atopic dermatitis vs. adult AD, there is 
a lack of research on how AD progresses into adulthood. The 2015 study conducted by 
Mortz et al. is one of the very few studies to explore this.  Persistent disease into adult life 
is quite common and negatively affects QoL.9 Patients with either early onset of disease 
or associated diseases such as allergic rhinitis and hand eczema are more likely for their 
AD to persist into adulthood. It is crucial to recognize AD as not only a common and 
debilitating disease of childhood, but also adulthood.9 
  There is much work to be done in improving interventions and preventing adverse 
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outcomes in the adolescent population. There is evidence to suggest that education and 
psychological coping could lessen the severity of AD.10 Multiple studies have explored 
alternative methods for healthcare delivery, but there are still many challenges in 
providing care for this population that needs to be addressed.  Providers working closely 
with adolescents are not frequently exposed to training modalities focusing on teaching 
strategies.  This education-based study will address how informing practitioners on the 
latest educational techniques and coping interventions can affect the QoL, symptoms, and 
management of adolescent AD patients.  
 
Hypothesis 
Providers will acquire adequate understanding of the most up-to-date educational 
interventions recommended for adolescents as an adjunctive treatment for AD, which will 
ultimately lead to positive provider-patient relationships.  
  
Objectives and specific aims 
The main purpose is to summarize and present the most recent data on education 
interventions and coping skills to providers in the format of a CME lecture. The goals of 
the lecture are to provide providers working with adolescents with AD the necessary 
tools to counsel individuals in the hopes of decreasing the likelihood of developing long-
lasting adverse effects on overall QoL and psychological consequences. If the hypothesis 
is correct, a new adjunct to topical and systemic treatments can be recommended for 
providers treating with adolescent patients with AD.  
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1. Identify education interventions associated with lower Scoring Atopic Dermatitis 
(SCORAD) score and improved QoL 
2. Summarize the current data on educational interventions that will increase 
compliance with treatment plan 
3. Create a CME lecture with a goal of educating providers on the latest literature on 
educational interventions in improving QoL for adolescents with AD 
4. Gauge pre- and post-assessment knowledge and understanding of AD therapy and 
evaluate the data with a paired t-test 
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REVIEW OF THE LITERATURE 
Overview 
Atopic dermatitis (AD), also known as chronic eczema, is a multifactorial chronic 
inflammatory skin disease, characterized by varying degrees of dry, scaly lesions, 
pruritus, and accompanying psychological burden. It can start at any age and often 
presents on uncomfortable areas such as the elbow, knee, and face but can appear all over 
the body as seen in Figure 1. It is a serious cause of QoL impairment, morbidity, and 
extremely high healthcare spending. It is thought to be caused by both genetic and 
environmental components.11 Atopy is the individualized or familial tendency to produce 
IgE antibodies in response to a low dose of proteins or allergens, which can cause 
diseases such as atopic dermatitis, asthma and allergic rhinoconjunctivitis.12 Eczema is 
often associated with these comorbidities and together are known as the atopic triad.13 
Clinical, genetic, and experimental studies have suggested that AD can be an antecedent 
for the development of sensitization resulting in allergic rhinitis and asthma. This 
highlights the importance of the epidermal barrier in the pathogenesis of these 
disorders.14 
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Figure 1. Varying stages of AD and dermatological changes associated with each.15 
 
 
 Atopic dermatitis usually manifests in early childhood, often before the age of 5, 
and affects areas of the face, neck, dorsal surfaces and joint flexural areas.16 Oftentimes, 
patients with a childhood onset outgrow the disease and have spontaneous remission 
before entering adolescence.17,18 Although AD is thought to be most common in children, 
up to 50% of cases can begin in or continue into adulthood. AD lesions can manifest as 
vesicular or papular lesions. In adolescents and adults, in addition to eczematous lesions, 
these older individuals often have overlying localized lichenified plaques, especially 
affecting the hands, the antecubital (Figure 2) and popliteal fossae. 
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Figure 2. Atopic dermatitis lesions with lichenified plaques affecting the antecubital 
fossae.19 
 
 Atopic dermatitis affects genders equally and is one of the most commonly 
diagnosed dermatological disorders in adolescents. According to the 2003 National 
Survey of Children’s Health, the incidence of atopic dermatitis is around 1 in 5 children, 
with a prevalence varying between 8.7 – 18.1% across states. After analyzing the national 
survey, Shaw et al. stated an odds ratio of 1.67 for correlative relationships between AD 
and factors such as metropolitan living, black race, higher education level, and dry 
climates.1 Other correlations include black race, higher education level, and dry climates. 
In comparison, atopic dermatitis affects 15-20% of children and 1-3% of adults 
worldwide.18  The incidence of atopic dermatitis is increasing; during past decades in 
several industrialized nations, the incidence has increased up to 3 times. Living in 
developed countries and metropolitan regions seems to be a risk factor for AD. Although 
the prevalence of AD is higher in developed countries and metropolitan regions, efforts to 
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identify specific environmental causes have been inconclusive.18 From 2000 to 2010, the 
prevalence of people younger than 17 years old with eczema has increased. According to 
the National Health Interview Survey, the CDC stated that prevalence of eczema or skin 
allergies has increased. Figure 3 shows that the prevalence  across racial groups has 
increased from “8.6% to 17.1% among non-Hispanic black children, from 5.0% to 9.9% 
among Hispanic children, and from 7.6% to 12.6% among non-Hispanic white 
children.”20  
 
Figure 3. Prevalence of AD or skin allergies across racial groups according to the 
CDC.20 
 
 
 
 
 9 
Risk factors for disease 
A heritable component has been recognized in the development of AD but does not 
follow typical Mendelian inheritance patterns and is thought to have a polygenic mode of 
inheritance. The most consistent risk factors for AD are family history and loss of 
function mutations of the FLG gene. Nearly 70% of AD patients have a family history of 
atopy.21,22 Chances of developing AD are 2-3 times higher in those with one atopic parent 
and 3-5 times higher if both parents have atopic syndromes.23,24 Flohr and Yeo suggests 
that limiting early childhood exposure to infectious agents, endotoxins, and animals can 
increase susceptibility to allergic diseases.25  
  Other risk factors include food sensitization, allergies, environmental factors, and 
microbial exposure. The most common food allergens associated with atopic dermatitis 
include cow’s milk, hen’s egg, and peanuts. It is thought that allergens can therefore be 
an exacerbating trigger for AD flare-ups.26 Environmental factors such as low outdoor 
temperature, urban settings, fast-food, delayed weaning, obesity, pollution, small 
families, widespread use of antibiotics, immunizations, and tobacco smoke are all 
associated with an increased risk for AD, while UV light exposure, fresh fruits, fish, and 
breastfeeding have been shown to be protective factors.18 
 
Pathophysiology 
There are three hypotheses proposed to account for the pathophysiology of the disease. 
The first is an immunological hypothesis that proposes strong contributions to atopic 
dermatitis results from dysregulation of adaptive and innate immune defense leading to 
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an amplified IgE-mediated, systemic Th2 response. 22 There is evidence to suggest that 
CD4+ T cells tend to follow predominately Th2 differentiation, which causes increased 
production of interleukins and IgE antibody.27 
  The second is a skin barrier hypothesis that proposes a loss of function gene 
mutation causing an impaired skin barrier leading to dry skin, fissuring, and a greater risk 
of eczema. Due to strong familial trends, investigators have tried to identify genes 
responsible for atopy. The strongest documented genetic association for AD is mutation 
of the filaggrin (FLG) gene, which is normally responsible in maintaining an intact and 
hydrated skin barrier.28 Atopic dermatitis affects 42% of all mutation carriers. FLG is 
normally responsible for an important epidermal protein expressed on the outer layers of 
the epidermis that help bind keratinocytes together.29  
  Lastly, the hygiene hypothesis states that excessive attention to hygiene, changes 
in eating habits, widespread use of antibiotics and immunization as seen with urban living 
will increase the risk of developing AD. The study conducted by Kramer et. al. supports 
this hypothesis as they found that AD prevalence was higher for children from small 
families (up to 3 people) and who attended a nursery at a later age compared to an earlier 
age.30 This study supports the idea that if the human immune system is exposed to 
infections and foreign antigens at an earlier age, then there would be greater protection 
against atopy.  Another example that supports the hygiene hypothesis showed that 
communities that strongly limited use of antibiotics and immunizations had a lower 
prevalence of AD.31 However, results from some studies do not support the hygiene 
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hypothesis. For example, studies by Zutavern et al. and Purvis et al. did not show any 
correlation between AD and the size of a family.32,33  
 Understanding psychological and emotional needs are crucial to treating patients 
holistically.34 Successful management in more than one-third of dermatology patients 
takes into account associated psychological factors. 35 Psychodermatology is a rapidly 
evolving field that examines the relationship between mind and skin. It focuses on the 
intricate interactions between the neuroendocrine, immune and cutaneous systems.36 This 
interplay is particularly applicable to atopic dermatitis, where patients can stress over its 
potentially lifelong or relapsing-remitting course.37   
 
Existing research 
Slattery et. al found that adolescents with AD had greater prevalence of anxiety disorders, 
such as depression and anxiety, when compared to the community.38 Stress is one of the 
many negative psychosocial impacts that atopic dermatitis has on adolescents. Studies 
have shown that stress exacerbates atopic dermatitis by inducing eosinophil, Th2, and IgE 
proliferation.16 In addition, both stress and atopic dermatitis occurring in childhood 
causes sensitization of the hypothalamic-pituitary-adrenal axis (HPA axis) increases the 
susceptibility to both in adulthood. By this rationale, if children with AD can control their 
AD and stress in childhood, then they will be less sensitive to stress when they are older. 
Psychotherapy, relaxation therapy, hypnosis, massage, and acupuncture are just a few of 
the many therapeutic approaches to reducing stress, relieve anxiety, and to change 
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behavioral patterns such as responses to itching and frustration that are common in AD 
patients.16 
  Sang Oh et al. evaluated the psychological traits of 34 adolescents afflicted with 
AD aged 13-41 with the following psychologically-based questionnaires: Beck 
Depression Inventory (BDI), State Trait Anxiety Index (STAI), Interaction anxiousness 
Scale (IAS), private body consciousness (PBC) and the Dermatology Life Quality Index 
(DLQI). Research found a significant relationship between the parameters of the 
questionnaires and DLQI as well as an increase in all parameters of the given 
questionnaires.39 Between the clinical factors, anxiety was found to be correlated to 
pruritus. Psychotherapy that can help decrease anxiety should be considered in patients 
with AD that do not respond to itch management by anti-histamines alone. 
  A study by Brenninkmeijer et al. of 165 patients aged 18-30 whose AD began 
during childhood highlighted the significant association between disease severity and 
negative impact on QoL with significant burden on QoL in 48.7% of patients 
(R=0.518,P<0.001).40 The major issues expressed were the desire to receive more 
understandable information about the disease, empathy from the provider, group 
interactions, and the need for psychological comfort. In addition, adolescent patients with 
moderate to severe AD exhibited notable hindrance in forming healthy social bonds, 
leading to having fewer friends and minimizing their output in group settings when 
compared to their healthy peers or those with mild AD. Patients in high school reported 
intense itching (90%), embarrassment of skin appearance (70%), intimate interaction 
avoidance (49.1%), abstinence of sports related activities (43.2%), sleep disruption 
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(69.2%), fatigue (60.2%) and physical aggravation of skin lesions associated with stress 
(74.1%).6  
  A correlation between severity of clinically significant symptoms and lesions and 
stress has been found. Saunes et al. conducted a study on Norwegian adolescents revealed 
a positive association between intensity of clinical attributes and amplification of 
psychological stress (p < 0.05).41 Specifically, females were found to be more impacted 
by psychological stress than males; however, the relationship between AD and 
psychological stress was more closely related in adolescent males than females. In 
particular, the psychological burden was most prevalent in patients ages 17-19 years 
old.41  It may be important to utilize screening tools to recognize these older individuals 
who are in distress.  
  There is recent evidence to suggest that educational interventions for both 
children and their caregivers may benefit from structured education provided by 
multidisciplinary teams.42 Atopic dermatitis in children significantly affects QoL by 
interfering with normal development, education, and play.43 Educational and counseling 
interventions can play an integral role in improving quality of life in  childhood and 
adolescence AD.  Education and counseling not only play an important role for the 
patients who are suffering from atopic dermatitis, but is equally essential for the patient’s 
family. As Lee and Oh mentioned, the more knowledge about AD that parents receive, 
the more motivated they are to treat it.43 Current interventions vary in their target 
population. Some interventions focus on integrated family education, some focus only on 
the affected child, and others focus only on counseling and educating the parents. The 
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variability in the types of intervention also vary greatly, including individual face-to-face 
educational sessions, web-based consultations, lectures, group discussions, practice 
scenarios, personal experience sessions, and structured activities. From allergists and 
dermatologists to psychologists and dieticians, educators of the interventions differ in 
their disciplines, but have all shown to be effective in counseling, educating, and 
motivating AD patients and family in self-managing the disease. Although the details of 
each intervention for AD are wide-ranging, most studies have shown that educational and 
counseling interventions are effective in improving the QoL in children and adolescents 
with AD.  
Interventions that lead to better outcomes can be simple and effective. For 
example, an intervention by Beattie and Lewis-Jones showed that merely demonstrating 
the application of topical therapies improve the outcome of treatment adherence44.  
Reasons for poor adherence to therapy include fear of side effects, under-prescribing, 
failure to renew medications, lack of time, refusal of therapy, and lack of knowledge of 
therapy. In Beattie and Lewis-Jones’ intervention, only 41% of patients who used topical 
corticosteroids were aware of its potency while a substantial number of patients also did 
not receive adequate information and training in the usage of topical therapies. By 
recommending the clear labelling of potency on topical corticosteroids and educating 
patients on how and when to use the medication, treatment adherence improved. With 
improved treatment adherence, better overall outcomes can be expected.  
  Interventions that target patients suffering from AD are conducted by educators 
from variable disciplines. However, it has been shown that a good educator-patient 
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relationship is the strongest predictor of adherence to treatment and strengthened self-
efficacy.45 Many studies have shown positive results from nurse educators. Patients 
reported faster access to treatment, increased knowledge of their condition, effective 
rapport without feeling rushed.46,47 These results indicate the types of educators that 
families and patients prefer for their educational and counseling interventions: educators 
that are available, knowledgeable, well-trained, and personable.  
  The format of the intervention also plays a role in its effectiveness. Although 
individualized educational interventions have been shown to decrease AD severity and 
increase QoL, group interventions seem to be more effective.48–50 Group interventions 
provide longer, more detailed sessions in addition to stimulating a sense of camaraderie 
by allowing families to share their stories, experiences, and questions. This way, families 
can learn what others do to help with the management of AD. Furthermore, some 
interventions take group interventions one step further by narrowing the group to 
comparable age ranges to help narrow the group’s focus. Futamara et al. conducted a 
two-day parental education program on childhood AD and compared results from a 
control group, who received conventional treatment alone, with results from a group 
receiving both conventional treatment and the parental education program. The study 
showed that group discussions helped to alleviate anxiety about AD. Results indicated 
that the experimental group had a much lower SCORAD score than the control group. 
The SCORAD determines severity of AD. According to the SCORAD index AD is 
defined as mild if <25, moderate 25-50, and severe if the score >50.51 In addition to the 
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lowered SCORAD score, the group receiving the educational program also received a 
better sleeplessness symptom score and corticosteroid anxiety score.  
  A German study conducted by Staab et al. performed an educational intervention 
among three age groups, 3 months to 7 years, 8 to 12 years, and 13 to 18 years.50  The 
program comprised of a two-hour group training once weekly for six weeks. The 3 
months to 7-year group received parental education while the 8 to 12-year group attended 
separate education sessions. The 13 to 18-year group attended individual sessions tailored 
to their needs based off medical, nutritional and psychological issues. Results indicated 
that the age-specific educational program had significantly better scores for severity of 
eczema, subjective severity, and effect on parents’ QoL as seen in Table 1 (p<0.05). 
Advantages of this study include narrow age groups, allowing Staab et al. to compare the 
differences between the age groups and usage of a control group, as improvements were 
also seen in the absence of parental or patient education. Another aspect of the study that 
is laudable is the 40-hour training workshop for educators. The program was only offered 
at institutions with national certification for the education of children and adolescents 
with AD. One limitation to this study is that only patients with moderate to severe 
eczema were included. It would be interesting to be how the same intervention affects 
patients with mild eczema as well.  
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Table 1. Comparisons of disease severity for AD between the intervention and 
control groups by Staab et al.50  
 
  
One study performed by Karppinen et al. assessed the effect of empowering 
heliotherapy on clinical outcome and quality of life for AD patients. Heliotherapy is 
treatment by exposure to sunlight. After two weeks of empowered heliotherapy 
consisting of group discussions, exercise practices, and heliotherapy, the SCORAD score 
for AD patients improved significantly, from 30.6 to 11.1 (p<0.001).52 Moreover, the 
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study was also done with psoriasis patients and results in QoL seemed to be more 
profound for AD patients. However, the two groups should not be directly compared due 
to the limited sample size. Although the results from the study showed important benefits 
of empowering heliotherapy, the experiment population only consisted of females. 
Females, as Uttjek et al. mentions, have been shown to have better topical treatment 
compliance than males.53 Therefore, the results of this study may be biased.  
Nevertheless, the intervention showed positive effects on AD symptoms and QoL by 
group discussions, lifestyle modifications, and treatment routines such as regular 
heliotherapy.  
  Many interventions are aimed toward educating the parents to improve child 
behavior problems, self-efficacy, QoL, treatment competence, and symptom severity. An 
intervention like the one performed by Morawska et al. educated parents of 2 to 10-year-
old children with atopic dermatitis using two 2-hour group discussions based on Triple P 
(Positive Parenting Program).54 Triple P is a family support system to prevent and treat 
behavioral problems in children and adolescents. The intervention group underwent 
didactic instruction, video modelling, active skills training, and homework assignments to 
educate the parents on AD, managing the illness, minimizing AD-associated stress, and 
ensuring optimal treatment implementation. Results indicated improved parents’ self-
efficacy, fewer eczema-related child behavior problems, improved management of 
eczema, better quality of life for the parents but not the child, reduced symptom severity, 
and no change in parental treatment compliance (p<0.001). 
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  Similarly, Pustisek et al. focused on understanding the significance of structured 
parental educational interventions on childhood AD by designing a short-term structured 
educational program for the parents of AD children ranging from ages 3 months to 7 
years. The results were like other intervention studies, where participants of the 
intervention had a much lower SCORAD score, with decreased pruritus (p = 0.000), sleep 
disturbance (p = 0.001), perceived stress (p = 0.024), and anxiety (p = 0.42)  than those of 
the control group.55  This study maintained small groups for their group sessions, ranging 
from 5 to 8 participants, to provide a better environment for focused communication. 
Moreover, Pustisek et al. thought that two 2-hour sessions would be the best format, as 
more people would be able to fit it in to their schedules, and is less expensive and easier 
to organize than longer sessions.  
  Educational and coping mechanism interventions seem to have positive effects for 
adults with AD as well. Ehlers et al. and Evers et al. both reported improvements in skin 
severity, reduced pruritus, and better management of AD after a multidisciplinary 
intervention utilizing educational sessions and cognitive-behavioral therapy.56,57 Some 
interventions, however, showed no difference between control groups and intervention 
groups. For example, Boston et al. developed a 12-week group-based program for adults 
with AD consisting of biweekly 2-hour sessions that include teaching topics such as skin 
disease, healthy lifestyle, stress management techniques, and medical feedback. After 
analyzing the results using variables such as disease severity, quality of life, symptoms, 
costs, and cost-effectiveness, the intervention group did not show any differences from 
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the control group at follow-up (p<0.05).58  The results however, could be attributable to 
the small sample size of 50 patients.  
  Overall, these multidisciplinary interventions often have many similarities in their 
structure and format, leading to similar results. Most of these interventions include 
educating the parents and patients on the disease and its management, incorporating 
group-sessions, and sometimes psychological and behavioral interventions.  These 
interventions are structured in a way that often allows the patient and family to be 
equipped with the knowledge needed to better manage AD, with the result of a better 
QoL. By learning about the pathophysiology, course, and triggers of the disease, the 
patient and family will be able to understand AD progression and avoid elements that 
may exacerbate the disease. By learning about treatment techniques and discussing the 
facts and myths of treatment side effects, patient concerns may be alleviated and 
treatment compliance may increase. Lastly, by utilizing group sessions, patients can share 
their personal experiences and concerns with the group to integrate knowledge such as 
tips, techniques, advantages and disadvantages of certain treatment methods.   
 The first step is to recognize the obstacles to successful disease management. To 
treat the whole individual, providers must pay more attention to understated contributors 
such as emotional strains and long-standing scratching habits. There is a need for 
providers to integrate educational and coping skills programs for effective disease 
management in affected youth. Implementations will likely significantly improve self-
perceived health, improve compliance, and reduce long-term psychological impact of 
disease.  
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 Studies that assess the pertinence of psychological impact on pathogenesis of AD 
are needed. Furthermore, dermatological providers must aim to understand psychological 
features of adolescents with AD. They must also become knowledgeable about the 
required treatment techniques in order to help patients control stressful states. The 
clinical features of AD are very well characterized; however, there are factors that 
predispose adolescents to persistence of disease. The disconcerting symptoms of AD in 
adolescences can become a vicious cycle with exacerbation of both the psychological and 
physical features of the condition. 
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METHODS 
Study design 
A curriculum on educational interventions for adolescents with AD will be designed for 
practitioners (including but not limited to physician assistants (PAs), physicians, and 
other health care providers). The aim will be to educate practitioners on the most up-to-
date knowledge on counseling and educational interventions specific to reducing and 
preventing AD associated comorbidities. The lecture will be conferred at nationally 
accredited continuing medical education (CME) conferences will facilitate gaining of 
new knowledge and skills to advocate for the ongoing improvement of adolescent patient 
care. The curriculum will be submitted for CME accreditation and offered for 1.5 
category 1 CME credits. 
 
Study population and sampling 
The presentation-based curriculum will be presented at national medical conferences 
offered to providers specializing in pediatrics, family medicine and dermatology, or those 
with a special interest in educational interventions. Based on an effect of 15% increase in 
scores from the pre-assessment to the post-assessment, an alpha level of 0.05 and a beta 
level of 0.80, the target sample size would be a minimum of 56 participants. If we 
presume that approximately 40 attendees attend each national conference. Therefore, the 
program must be offered at a minimum of 2 nationals conferences in order to attain our 
goal sample size. 
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The target conferences are those offered through American Academy of 
Dermatology (AAD), American Academy of Physician Assistants (AAPA), Society of 
Dermatology Physician Assistants (SDPA), Society for Pediatric Dermatology (SPD), 
American Academy of Family Practitioners (AAFP) and AAP (American Academy of 
Pediatrics). All medical health providers working in pediatrics or dermatology will be 
invited to the 90-minute presentation on incorporating education and psychosocial 
interventions into AD therapy. 
 
Curriculum 
The content of the lecture will be a general overview of the most current research on the 
recommendations for educational interventions for adolescents with AD. The design will 
be in the structure of a PowerPoint presentation accompanied by multiple image-based 
slides. Curriculum will be developed by dermatology experts actively involved in AD 
clinical research and education. The target learning audience is providers working 
frequently with the adolescent population who could be afflicted by AD. The first live 
didactic session is a 90-minute slide presentation entitled “Educational interventions in 
Adolescents with Atopic Dermatitis”. The framework of the lecture will be centered 
around the learning objectives which will serve as a guide for key takeaway points. 
Responses to the pre-test and post-test portion comprised of 10 questions will be 
completed by attendants through mobile audience response systems (mARS). The 
advantage of mARS is that other data points can be documented anonymously including 
text responses. There will be three sections to the supplementary short answer portion 
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which will be sent out as an electronic survey via email subsequent to the conference. For 
the first, the attendees will create a short provider-patient dialogue to educate patients on 
stress management. For the second, participants will identify potential barriers to 
implementing changes to their practice such as time constraints, issues with 
administrative advocacy insurance claims, or lack of professional standards. The last 
short answer will address any changes they would hope for in future presentations. 
 
Table 2. CME Learning Objectives 
1. Understand the scope of current treatment options for adolescents with AD 
2. Apply current data from clinical trials for educational interventions and 
individualization of treatment 
3. Recognize importance of timely initiation of educational interventions including 
improvements in patient comprehension, group therapy, structured teaching of 
treatment, and coaching coping strategies 
4. Identify when to implement strategies for overcoming barriers to access to care and 
patient therapy adherence 
5. Explain interdisciplinary team and collaborative care approaches that can improve 
patient outcomes 
6. Design treatment plans that align with individualized patient and family goals 
7. Devise a provider-patient dialogue to educate patients on disease pathogenesis, 
proper treatment techniques, stress management, and adherence in AD care. 
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Table 3. CME Question topics 
1.  Defining atopic dermatitis (AD) 
2.  Pathophysiology of AD  
3. Current available treatment options for AD 
4. Comorbidities associated with chronic AD 
5. Psychological coping strategies 
6. Structure of educational interventions for adolescents with AD 
7.  Effectiveness of educational interventions on lowering SCORAD and 
improving QoL 
8.  Effect of group therapy on adolescents with AD 
9.  Creating successful provider-patient dialogues 
10. Provider confidence in integrating education and counseling of adolescent 
patients with AD into their clinical practice 
 
Curriculum Assessment 
While the CME learning objectives will highlight the key points, the primary evaluation 
of how efficacious the curriculum is will be determined through the pre- and post- test 
data.  The pre-test will be completed via mARS serve to identify baseline knowledge 
prior to the lecture. Immediately following the PowerPoint lecture, the post-test 
questionnaire will be administered through mARS by all health care professionals in 
attendance.  
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Study variables and measures 
Each audience member will perform both pre- and post- lecture assessments to determine 
success and impact of educational session. The supplemental short answer portion where 
participants create a brief provider-patient dialogue will be for educational purposes only 
and will not be graded. Pre- and post- activity questions to measure baseline and 
immediate changes in declarative knowledge (Moore’s level 3A). The pre- and post- tests 
will be identical and be comprised of 10 questions answered through mobile audience 
response systems (mARS). Each attendee will be encouraged to bring their own web/html 
capable device. Devices may be leased upon entry for those who do not own compatible 
devices. The hope is that the post-lecture data will show a minimum of 15% increase in 
scores and a minimum score of 80%. A target 80% score correlates with answering 8 out 
of 10 questions correctly on the post-test. The questions will be comprised of topics 
covered in the learning objectives listed in Table 2. 
 
Recruitment 
All participants included in the study will have attended the 90-minute lecture offered at 
certified CME conferences. Ideally, the attendees will be health care providers who 
specialize in dermatology and/or pediatrics or have a special interested in educational 
interventions in adolescents. The certified 1.5 CME credit course can be place towards 
their required by their state. Additionally, this CME course is a great opportunity for 
attendees to learn more regarding recently developed areas specific to education in 
pediatric dermatology. After specific conferences are scheduled the presentation will be 
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publicized on national organization webpage and the CME webpage. Handouts and 
information will be distributed at selected academic medical centers, an email marketing 
campaign, as well as social media accounts associated with upcoming national medical 
conferences. Advertisements will include title, time and date of each presentations, names 
of speakers, brief overview of presentation agenda. To be included in the study, each 
attendee must also sign consent forms giving permission for their participation in the 
educational program. 
 
Data collection 
All audience data will be collected through mARS and through an additional electronic 
survey which are both useful instruments to assess audience comprehension. By utilizing 
this system, the audience can not only answer multiple choice questions but also submit 
text responses for open-ended questions. It also allows the educator to receive 
instantaneous anonymous responses demonstrating the learners understanding of topics. 
All pre-test data will be recorded prior to formal commencement of the lecture. Post-test 
data will be acquired at the end of the presentation. 
Other data elements collected from the conference include: anonymized attendee 
evaluations of the CME lecture, audience demographics, and short answer responses. 
Attendee evaluations of the course will be based on a five point Likert scale in the six 
domains listed below in Table 4 on delivery, content and practical value. Evaluations of 
the CME will be to evaluate aspects of overall course and how well it contributed to 
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educational value. Audience demographics will also be documented at the end of the 
lecture. 
 
Table 4. Evaluation of Continuing Medical Education  
1. Pre-course registration 
 
2. Quality of course information 
 
3. Delivery of CME presentation 
 
4. Overall organization of lecture 
 
5. Relevance to clinical practice  
 
6. Opportunity for engagement  
 
 
Table 5.  Five point Likert scale 
1=Poor 
2= Fair 
3=Neutral 
4= Good 
5=Excellent 
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Table 6. Audience Demographics Survey 
1. Which of the following best describes your primary professional credential? 
a) Physician Assistant 
b) Physician (MD, DO) 
c) Nurse Practitioner 
d) Nurse 
e) Other (OT, PT, PhD, PharmD) 
2. Which of the following best describes your age group? 
a) Under 30 years 
b)  30 to 40 years 
c)  40 to 50 years 
d)  50 to 60 year 
e) Over 65 years 
 
3. Which best describes your clinical practice environment? 
a) Community 
b) Hospital 
c) Academic Medical center 
d) Outpatient practice 
e) Other (Industry, Lab) 
 
4. Which of the following describes your primary area of practice? 
a) Pediatrics 
b) Dermatology 
c) Primary Care 
d) Mental Health 
e) Other 
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Data analysis 
At the end of one calendar year, all the data will be entered into Microsoft Excel-based 
study report form and an analysis will be performed using IBM SPSS. Paired t-test will 
be used to evaluate and summarize the pre- and post- CME mean test scores for outcomes 
related to knowledge and competence (Moore’s framework levels 3 and 4 respectively). 
Chi-square tests or t-tests will be conducted to compare demographic characteristics of 
physician assistants, physicians, and other providers. 
 
Timeline and resources 
Prior to launching the presentation, the lecture must be first accredited by the 
Accreditation Council for Continuing Medical Education (ACCME) as well as the 
American Academy of Physician Assistants (AAPA).  Accreditation is essential for 
confirming that the presentation is up to standard and can be used by practitioners in their 
incorporation of new knowledge to better care.  First time applicants applying for initial 
accreditation through the ACCME can take approximately twelve to eighteen months.  
The goal will be to achieve provisional accreditation for a two-year term. Applications 
for AAPA Category 1 CME credit submitted for live conference which must be 
submitted at least 21 days prior to activity start date, thereby allowing 3 weeks for review 
by the AAPA Review Panel. Once approved the AAPA CME Accreditation will be valid 
for one calendar year. The plan will be to submit all applications by January 2017 with 
expected approval from both accrediting bodies by September 2018. Anticipated 
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completion of data collection will be September 2019. Presenting faculty will disclose 
limitations of data and potential conflicts of interest, if anyt. 
The goal is to offer this lecture at many wide-ranging medical conferences in the United 
States throughout the year. As soon as accreditation is received, we will begin to offer the 
lecture at national conferences offered to various health care providers. Offering to 
lecture to mid-level practitioners and physicians will allow for more extensive outreach 
and strengthen statistical analyses. 
 
Institutional Review Board 
The study protocol will be sent for Institutional Review Board (IRB) exemption for 
educational studies of Boston Medical Center and Boston University Medical 
Campus IRB under the 45 CFR 46.101 (b) criteria. 
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CONCLUSION 
Discussion 
Education is critical to the management of all diseases. Current literaturesuggests that 
educational interventions provided by multidisciplinary teams are effective for 
adolescents with atopic dermatitis. Better disease control at an early age can equip 
patients with the knowledge and tools they need to adhere to treatment regimens and 
prevent future physical and psychological complications. Research also suggests that a 
strong provider-patient relationship may be the most important prognosticator of 
adherence to treatment and self-sufficiency.  
  By reaching out to the medical community with a CME curriculum on educational 
interventions for atopic dermatitis, there is the potential to affect a wide population of 
patients. The design of the proposed CME-accredited lecture makes it an enticing 
motivator for attendees to earn CME credit and ensures reliable attendance while learning 
about optimizing therapy. The curriculum will be applicable to physician assistants, nurse 
practitioners, and physicians working in pediatrics, family practice, and dermatology 
fields who will encounter many patients afflicted by this lifelong skin condition. 
Additionally, the curriculum aims to inspire providers to express greater interest in 
patient advocacy and teaching. Providers attending the conferences are subsequently 
more likely to be involved in passing on their new skillset and educational techniques. 
The curriculum will have the greatest chance of success if providers with a fundamental 
understanding of pediatrics and dermatology genuinely aspire to learn about educational 
techniques. If the educational session is successful, the lecture can be adapted to atopic 
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dermatitis patients of all ages.  To verify whether the learning objectives are met, both a 
pre- and post-lecture assessment will be administered. One potential limitation of this 
study is  that our statistical analysis may not reach signficicance if we cannot recruit the 
target sample size population of 56 attendance. However, it should not be difficult to 
meet the target sample size by presenting at more than one national conference for 
multiple organizations.  
 
Summary 
AD is one of the most common chronic inflammatory skin diseases and a major public 
health concern globally. In many instances, those who are diagnosed with AD continue to 
have persistent disease and symptoms throughout their adult life. Given the potentially 
lifelong course with no cure, there is a need for adjunctive patient-focused treatments. 
Current research indicates that educational interventions are effective in creating a 
positive impact on QoL, reducing psychological sequelae and disease severity, and 
motivating AD patients to adhere to treatment regimens. In particular, practitioners 
should be aware that poor coping and long-established scratching can play a major role in 
the exacerbation of symptoms. Designing a curriculum to teach providers how to 
recognize patient knowledge deficiencies and approach psychological suffering is 
essential to create better outcomes. Poor tactics and poor communication skills when 
addressing discouraged patients can sometimes amplify negative outcomes. It is 
necessary to provide health specialists with the proper tools to carry out interventions 
aimed at improving knowledge, improving AD disease management, and problem 
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solving skills. Teaching interventions can also include lecture material on psychological 
management targeting self-efficacy and coping mechanisms. Effective completion of the 
curriculum will give providers relevant instructive and clinically-based training for a 
specific age population, allowing them to be better equipped to care for adolescents with 
atopic dermatitis. 
 Adolescence is comprised of formative years of development that are critical in 
influencing perceptions about atopic dermatitis and therapeutic plans for self care. 
Equipping and empowering providers to take action and practice age-appropriate 
initiatives will enhance their expertise in responding to their adolescent AD patients.  The 
curriculum, as an added benefit, will improve and build a healthy patient-provider 
relationship. By conducting this research, more medical professionals will practice a 
holistic approach to managing AD. This CME course will act as a foundation to build a 
comprehensive and effective therapy for young teens with AD. This study aims to 
confirm that educational lectures are imperative in continuing medical education and 
furthering clinical expertise. 
 
Clinical and/or public health significance 
It is important to address AD because the physical symptoms of painful, dry, itchy skin 
can lead to poor sleep, lower QoL, emotional distress and affect activities of daily living. 
This research aims to show that providers who have taken the curriculum will be 
confident in managing and approaching adolescent patients. If the aims are fulfilled, then 
it is expected that the curriculum will become a meaningful component of future CME 
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conferences. This study data has the potential of influencing academic medical centers to 
emphasize education interventions when educating trainees early on in their careers. 
Offering this curriculum at annual CME conferences will allow practitioners nationwide 
to treat their AD patients by using the most effective combination of therapies to 
minimizes the impact of disease.  
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